Overview

Trial of Combination Therapy to Treat COVID-19 Infection

Status:
Active, not recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
In this trial patients will be treated with either a combination of therapies to treat COVID-19 or a placebo. Treatment will last 10 days, and patients will be followed for 6 months.
Phase:
Phase 1
Details
Lead Sponsor:
ProgenaBiome
Collaborator:
Topelia Therapeutics
Treatments:
Ascorbic Acid
Cholecalciferol
Doxycycline
Ivermectin
Vitamin D
Vitamins
Zinc
Zinc Sulfate